SIREN : 500806633
ADHEXPHARMA is a French company founded 18 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in PARIS (75016), this company of category ETI shows in 2019 a revenue of 23.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2019 | 2018 | 2016 |
|---|---|---|---|
| Revenue | 23 811 191 € | 15 446 917 € | 9 886 355 € |
| Net income | 2 770 662 € | 1 660 824 € | 633 365 € |
| EBITDA | 6 688 190 € | 4 170 190 € | 2 309 606 € |
| Net margin | 11.6% | 10.8% | 6.4% |
In 2019, ADHEXPHARMA achieves revenue of 23.8 M€. Over the period 2016-2019, the company shows strong growth with a CAGR (compound annual growth rate) of +34.0%. Vs 2018, growth of +54% (15.4 M€ -> 23.8 M€). After deducting consumption (7.2 M€), gross margin stands at 16.6 M€, i.e. a rate of 70%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 6.7 M€, representing 28.1% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.8 M€, i.e. 11.6% of revenue. This profit can be retained or distributed to shareholders.
23 811 191 €
16 648 110 €
6 688 190 €
3 887 306 €
2 770 662 €
28.1%
The debt ratio (= Financial debt / Equity x 100) stands at 130%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 33%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.3 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 18.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
130.158%
33.226%
18.48%
2.321
69.6%
In 2019, the debt ratio of ADHEXPHARMA (130.16) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2019, the financial autonomy of ADHEXPHARMA (33.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2019, the repayment capacity of ADHEXPHARMA (2.32) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 239.19. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.9x. Danger: operating income does not cover interest charges, unsustainable situation.
239.194
0.922
In 2019, the liquidity ratio of ADHEXPHARMA (239.19) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2019, the interest coverage of ADHEXPHARMA (0.9x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 67 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 83 days. Favorable situation: supplier credit is longer than customer credit by 16 days. Inventory turnover is 70 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 122 days of revenue, i.e. 8.1 M€ to permanently finance. Over 2016-2019, WCR increased by +150%, requiring additional financing.
8 055 564 €
67 j
83 j
70 j
122 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 552 800€ to 1 699 092€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ADHEXPHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of ADHEXPHARMA in 2019 is 23.8 M€.
Yes, ADHEXPHARMA generated a net profit of 2.8 M€ in 2019.
The headquarters of ADHEXPHARMA is located in PARIS (75016), in the department Paris.
The tax return of ADHEXPHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ADHEXPHARMA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.